GHRH(1-29) analogue for endogenous GH research.
Sermorelin is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone, the shortest fragment retaining full biological activity.
Binds pituitary GHRH receptors to stimulate endogenous, pulsatile GH release under physiological feedback.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Reviewed sermorelin as alternative to recombinant GH in adult-onset deficiency.
Supported pulsatile-GH advantage and preserved feedback regulation.
Long-term [Nle27]-GHRH(1-29) on endocrine and metabolic markers.
Restored GH/IGF-1 toward younger-adult range with metabolic improvements.
Single nightly injections of GHRH(1-29) in healthy elderly men.
Increased nocturnal GH pulses and IGF-1 vs. placebo.
Lyophilized 2–8°C. Reconstituted: 2–8°C, 14 days.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Sermorelin is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
